DNA in sarcoma shows 89% sensitivity, while Indian data shows declining protein intake, highlighting personalized care and ...

Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of ...

Adaptimmune Therapeutics plc (NASDAQ: ADAP) Q1 2025 Earnings Call Transcript May 13, 2025 Adaptimmune Therapeutics plc beats ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...